Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| 5-Amino-1MQ | AOD-9604 | |
|---|---|---|
| Category | Peptides | Growth Factors |
| Standard Dose | Research indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses. | Research indicates 250-300 mcg daily via subcutaneous injection, administered in the morning on an empty stomach. |
| Timing | Morning dosing preferred. Can be taken with or without food. | Morning administration on empty stomach, at least 30 minutes before eating. Fasted state enhances lipolytic effect. |
| Cycle Duration | 8-12 week cycles. | 12-20 week cycles. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA). By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ levels, reduces 1-MNA production, suppresses lipogenesis in adipocytes, and modulates the methionine-homocysteine cycle. In vivo, it significantly reduces body weight, white adipose mass, and adipocyte size through enhanced energy expenditure and altered lipid metabolism.
Research indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.
Morning dosing preferred. Can be taken with or without food.
8-12 week cycles.
AOD-9604 is a synthetic 16-amino acid fragment (residues 176-191) of the C-terminal domain of human growth hormone with a tyrosine substitution at the N-terminus. It selectively stimulates lipolysis by upregulating beta-3 adrenergic receptors in adipose tissue while inhibiting lipogenesis. It modulates lipid and glucose metabolism through beta-adrenergic and AMPK-related pathways without influencing IGF-1 activity, growth, or insulin sensitivity — retaining GH's fat-burning properties without its growth-promoting effects.
Research indicates 250-300 mcg daily via subcutaneous injection, administered in the morning on an empty stomach.
Morning administration on empty stomach, at least 30 minutes before eating. Fasted state enhances lipolytic effect.
12-20 week cycles.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →